169
More people living with haemophilia A in the UK will be able to get access to a subcutaneous treatment, Roche/Chugai’s Hemlibra, thanks to a decision by NHS England to make it an option for all patients.
Hemlibra (emicizumab), the only treatment currently available for haemophilia A via the NHS that doesn’t require an intravenous infusion, can now be used as prophylaxis in patients of all ages with moderate haemophilia A. Previously, it could only be used in patients at the severe end of the spectrum
Hemlibra was licensed by the MHRA for people of all ages with moderate haemophilia A, with a…